Actively Recruiting
Registry Study on Tagraxofusp ELZONRIS Treatment in Adults with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN
Led by Stemline Therapeutics, Inc. · Updated on 2026-08-25
80
Participants Needed
41
Research Sites
91 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of tagraxofusp in adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN, focusing on how well the treatment works and its safety in typical clinical settings. This observational registry study aims to gather real-world data on patients who are either new to tagraxofusp treatment or have relapsedrefractory disease after prior therapies. The study is sponsored by Stemline Therapeutics, Inc. and seeks to understand treatment outcomes in everyday medical practice. Participants in this study are adults diagnosed with BPDCN who are prescribed tagraxofusp monotherapy, either as first-line treatment or after relapse. The study does not provide the medication instead, it observes patients receiving tagraxofusp through their usual care. Two groups are included those newly starting tagraxofusp and those who have relapsed or are refractory to other treatments. The study tracks these patients over time to evaluate treatment responses and safety. Participants will be monitored for up to several years, with key assessments including the number of participants achieving complete response after about 3 months of treatment and the occurrence of capillary leak syndrome up to approximately 51 months. Additional outcomes include stem cell transplant rates, progression-free survival, overall survival, response duration, adverse events, and treatment dosing details up to 66 months. The study involves regular data collection from medical records and clinical follow-ups to assess these outcomes and track patient safety throughout the observation period.
CONDITIONS
Brief Title
A Registry-study of ELZONRIS in Participants With BPDCN
Research Team
S
Stemline Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here